AIM advances Ampligen’s Phase 2 pancreatic-cancer study and clinical strategy

Sep 9, 2026 13:03 (45d ago)

Verifying

AIM ImmunoTech released a CEO Corner installment on Ampligen’s pancreatic-cancer strategy.
Phase 2 DURIPANC is testing Ampligen with durvalumab as maintenance therapy.
AIM expects primary-endpoint analysis, biomarker evaluation and overall-survival follow-up.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.